SAN DIEGO --(BUSINESS WIRE)--Sep. 7, 2023-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that data from its functional

- Seralutinib Phase 3 PROSERA Study in PAH Patients Expected to Initiate in 3Q23 - - Additional Data from TORREY Open-Label Extension Expected in 4Q23 or 1Q24 -   - $374 Million in Cash, Cash Equivalents & Marketable Securities , as of June 30, 2023 , Pro Forma for Gross Proceeds of $212 Million

- Call will be held on Tuesday, July 25 th beginning at 10 a.m. EDT - SAN DIEGO --(BUSINESS WIRE)--Jul. 24, 2023-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial

- In Conjunction with Offering, Interim TORREY OLE Data and PROSERA Phase 3 Design Disclosed via 8-K; Conference Call to Discuss Data and Phase 3 Design with Leading PAH KOLs to be Held on July 25 th - SAN DIEGO --(BUSINESS WIRE)--Jul. 20, 2023-- Gossamer Bio, Inc.

SAN DIEGO --(BUSINESS WIRE)--May 18, 2023-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced data from its Phase 2 TORREY Study of

- Feedback on Planned Registrational Program for Seralutinib Received from FDA and EMA following Successful Phase 2 TORREY Study - - Registrational Phase 3 Clinical Trial in PAH Patients Expected to Initiate in 3Q23 - - Initial TORREY Study Open-Label Extension Data Expected Mid 2023 - -

- FDA Feedback on Seralutinib Phase 3 Clinical Trial Received; Expected to Commence in the Second Half of 2023 - - Topline Data from TORREY Study Open-Label Extension Expected in Mid-2023 - - Enrollment in GB5121 Phase 1b/2 Clinical Trial in PCNSL Paused - - Cash, cash equivalents and marketable